Education
About Us
Working with TipRanks
Follow Us
APONTIS PHARMA AG (DE:APPH)
XETRA:APPH
APPH Stock Chart & Stats
€11.00
-€0.05(-0.47%)
At close: 4:00 PM EST
€11.00
-€0.05(-0.47%)
Day’s Range― - ―
52-Week Range€10.00 - €12.35
Previous CloseN/A
Volume747.00
Average Volume (3M)1.98K
Market Cap
€93.50M
Enterprise Value€79.42M
Total Cash (Recent Filing)€11.38M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)139.9
Beta0.11
Next Earnings
Mar 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.07
Shares Outstanding8,500,000
10 Day Avg. Volume3,296
30 Day Avg. Volume1,977
Financial Highlights & Ratios
PEG Ratio-1.04
Price to Book (P/B)2.70
Price to Sales (P/S)1.73
P/FCF Ratio-15.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Sell
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
APPH FAQ
What was APONTIS PHARMA AG’s price range in the past 12 months?
APONTIS PHARMA AG lowest stock price was €10.00 and its highest was €12.35 in the past 12 months.
What is APONTIS PHARMA AG’s market cap?
APONTIS PHARMA AG’s market cap is €93.50M.
When is APONTIS PHARMA AG’s upcoming earnings report date?
APONTIS PHARMA AG’s upcoming earnings report date is Mar 05, 2026 which is in 66 days.
How were APONTIS PHARMA AG’s earnings last quarter?
APONTIS PHARMA AG released its earnings results on Nov 06, 2025. The company reported €0.072 earnings per share for the quarter, beating the consensus estimate of N/A by €0.072.
Is APONTIS PHARMA AG overvalued?
According to Wall Street analysts APONTIS PHARMA AG’s price is currently Overvalued.
Does APONTIS PHARMA AG pay dividends?
APONTIS PHARMA AG does not currently pay dividends.
What is APONTIS PHARMA AG’s EPS estimate?
APONTIS PHARMA AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does APONTIS PHARMA AG have?
APONTIS PHARMA AG has 8,500,000 shares outstanding.
What happened to APONTIS PHARMA AG’s price movement after its last earnings report?
APONTIS PHARMA AG reported an EPS of €0.072 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.376%.
Which hedge fund is a major shareholder of APONTIS PHARMA AG?
Currently, no hedge funds are holding shares in DE:APPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
APONTIS PHARMA AG Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
12.31%
12-Months-Change
Fundamentals
Return on Equity
2.09%
Trailing 12-Months
Asset Growth
-8.75%
Trailing 12-Months
Company Description
APONTIS PHARMA AG
Apontis Pharma AG markets and sells medical drugs for indication fields of internal medicine in Germany. It develops, promotes, and sells a portfolio of single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, hyperlipidemia, and secondary prevention, as well as respiratory diseases and diabetes. The company was founded in 1946 is headquartered in Monheim am Rhein, Germany.